MedTrace Logo

Safety of Expanded Haploidentical Natural Killer Cells for Leukemia

NCT04327037 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-03-02

No results posted yet for this study

Summary

The purpose of this study is to estimate the safety of ex vivo expanded haploidentical natural killer (NK) cells for patients with leukemia.

Conditions

  • Leukemia, Acute Myeloid
  • Leukemia, Acute Lymphoblastic

Interventions

BIOLOGICAL

Expanded Haploidentical Natural Killer cells

One dose (from 20x to \>100x 10\^6 /kg) of expanded haploidentical NK cells

DRUG

IL-2

6 doses of IL-2 (1 × 10\^6 units/m2) from -1 day every other day.

Sponsors & Collaborators

  • Belarusian Research Center for Pediatric Oncology, Hematology and Immunology

    lead OTHER

Principal Investigators

  • Olga Aleinikova · Belarussian Research Center for Pediatric Oncology, Hematology and Immunology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-02
Primary Completion
2021-06-06
Completion
2021-06-30

Countries

  • Belarus

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04327037 on ClinicalTrials.gov